JPWO2020074902A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020074902A5
JPWO2020074902A5 JP2021519114A JP2021519114A JPWO2020074902A5 JP WO2020074902 A5 JPWO2020074902 A5 JP WO2020074902A5 JP 2021519114 A JP2021519114 A JP 2021519114A JP 2021519114 A JP2021519114 A JP 2021519114A JP WO2020074902 A5 JPWO2020074902 A5 JP WO2020074902A5
Authority
JP
Japan
Prior art keywords
vaccinia virus
virus vector
scr4
scr3
scr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519114A
Other languages
English (en)
Japanese (ja)
Other versions
JP7410139B2 (ja
JP2022502066A (ja
JP2022502066A5 (https=
Publication date
Priority claimed from GBGB1816547.2A external-priority patent/GB201816547D0/en
Application filed filed Critical
Publication of JP2022502066A publication Critical patent/JP2022502066A/ja
Publication of JPWO2020074902A5 publication Critical patent/JPWO2020074902A5/ja
Publication of JP2022502066A5 publication Critical patent/JP2022502066A5/ja
Application granted granted Critical
Publication of JP7410139B2 publication Critical patent/JP7410139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519114A 2018-10-10 2019-10-10 癌治療のための修飾b5r遺伝子を有する腫瘍溶解性ワクシニアウイルス Active JP7410139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1816547.2A GB201816547D0 (en) 2018-10-10 2018-10-10 Oncolytic virus for the treatment of cancer
GB1816547.2 2018-10-10
PCT/GB2019/052877 WO2020074902A1 (en) 2018-10-10 2019-10-10 Oncolytic vaccinia virus with modified b5r gene for the treatment of cancer

Publications (4)

Publication Number Publication Date
JP2022502066A JP2022502066A (ja) 2022-01-11
JPWO2020074902A5 true JPWO2020074902A5 (https=) 2022-10-04
JP2022502066A5 JP2022502066A5 (https=) 2022-10-04
JP7410139B2 JP7410139B2 (ja) 2024-01-09

Family

ID=64397608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519114A Active JP7410139B2 (ja) 2018-10-10 2019-10-10 癌治療のための修飾b5r遺伝子を有する腫瘍溶解性ワクシニアウイルス

Country Status (8)

Country Link
US (1) US12509704B2 (https=)
EP (1) EP3863669A1 (https=)
JP (1) JP7410139B2 (https=)
KR (1) KR102937548B1 (https=)
CN (1) CN113453713A (https=)
CA (1) CA3123973A1 (https=)
GB (1) GB201816547D0 (https=)
WO (1) WO2020074902A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250044313A (ko) * 2022-07-27 2025-03-31 아스트라제네카 아베 Pd-1/pd-l1 저해제와 인터루킨-12를 발현하는 재조합 바이러스의 조합물
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5547862A (en) 1993-07-29 1996-08-20 Ambion Inc. Vectors containing multiple promoters in the same orientation
FR2757178B1 (fr) 1996-12-13 1999-03-05 Centre Nat Rech Scient Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament
US5955310A (en) 1998-02-26 1999-09-21 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide in a bacillus cell
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100354441B1 (en) 2000-12-27 2002-09-28 Samsung Electronics Co Ltd Method for fabricating spin-on-glass insulation layer of semiconductor device
CA2481304A1 (en) 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
AU2005222084B2 (en) 2004-03-05 2010-04-22 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAI agents
KR101772375B1 (ko) 2005-09-07 2017-08-29 신라젠(주) Gm-csf를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
BRPI0618441B8 (pt) 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20090196905A1 (en) 2008-02-06 2009-08-06 Spada Lon T Stabilization of mitochondrial membranes in ocular diseases and conditions
CN101658670A (zh) 2008-08-25 2010-03-03 中国疾病预防控制中心性病艾滋病预防控制中心 基于n1l和b8r基因缺失的痘苗病毒载体的艾滋病疫苗
ES2585242T3 (es) * 2008-09-19 2016-10-04 Etat Francais Représenté Par Le Directeur Central Du Service De Santé Des Armées Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas
EP2199400A1 (en) 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
US20100291182A1 (en) 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
CA3186189A1 (en) 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
ES2362525B8 (es) 2009-10-08 2013-01-03 Azurebio, S.L. Formulación de medicamentos en forma de agujas percutaneas penetrantes.
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
WO2011125469A1 (ja) 2010-04-09 2011-10-13 国立大学法人東京大学 マイクロrna制御組換えワクシニアウイルス及びその使用
US20120271272A1 (en) 2010-10-15 2012-10-25 Iscience Interventional Corporation Device for ocular access
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US9284588B2 (en) 2010-12-16 2016-03-15 Novozymes, Inc. Promoters for expressing genes in a fungal cell
CN103110939A (zh) 2012-10-23 2013-05-22 郑州大学 诱导肿瘤特异性免疫的疫苗及其应用
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
WO2017014296A1 (ja) * 2015-07-22 2017-01-26 国立大学法人鳥取大学 ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子
US10888594B2 (en) * 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
WO2018049261A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators

Similar Documents

Publication Publication Date Title
KR101114784B1 (ko) 아데노바이러스 벡터 백신
JP4472250B2 (ja) 高発現可能遺伝子
Kirk et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy
Fakhrai et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.
Bermúdez-Humarán et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production
Pasquini et al. Cytokines and costimulatory molecules as genetic adjuvants
JP2006141398A5 (https=)
JP2025023916A5 (https=)
US8293252B2 (en) Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization
JPWO2019173798A5 (https=)
JP2022502066A5 (https=)
JPWO2020124274A5 (https=)
Ma et al. Coimmunization with RANTES plasmid polarized Th1 immune response against hepatitis B virus envelope via recruitment of dendritic cells
JPWO2020074902A5 (https=)
JP4719876B2 (ja) Hlaクラスii拘束性wt1抗原ペプチド
KR100788930B1 (ko) 항암 조성물
CZ20011521A3 (cs) Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek
Frauenschuh et al. Differential polarization of immune responses by co-administration of antigens with chemokines
TWI259206B (en) A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof
EP0546099B1 (en) Use of human Interferon gamma 4-134
JPWO2020188348A5 (https=)
AU2021236879A1 (en) A mixture of mRNA to enhance the potency of dendritic cells
Channarong et al. Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine
WO2020214203A1 (en) Replication deficient adenoviral vectors for hiv vaccine applications
Chiang et al. Tumor-directed cytokine gene therapy